AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac conditions. Characterized by amyloid protein deposition ...

A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk ...

Amyloidosis is a group of conditions that cause an abnormal protein called amyloid to build up in the body. Treatment depends on the type of amyloidosis but may include medications and organ ...

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

Amyloidosis is a rare and possibly life-threatening disease affecting an estimated 4,000 people per year in the US. If left untreated, the disease can cause severe organ damage, so early detection is ...

Amyloidosis is a rare category of disorders in which various cells in your body function abnormally, leading to the buildup of amyloid protein. Symptoms, prognosis, diagnosis, and treatment depend ...

Amyloidosis is a condition that affects various body tissues and organs. Learn 8 ways it affects the body, and what you can do to manage these symptoms.

So, amyloidosis, there are several types, several causes, and several symptoms, so you need a comprehensive team to get together and put this puzzle together. Interviewer: Yeah, and we have a clinic ...